Ascletis Pharma Inc (2VJ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has a cash flow conversion efficiency ratio of -0.013x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-33.98 Million ≈ $-39.73 Million USD) by net assets (€2.57 Billion ≈ $3.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ascletis Pharma Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Ascletis Pharma Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Ascletis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ascletis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascletis Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yunnan Salt & Salt Chemical Industry Co Ltd
SHE:002053
|
0.031x |
|
Wuxi Zhenhua Auto Parts Co. Ltd.
SHG:605319
|
0.081x |
|
UTI Asset Management Company Limited
NSE:UTIAMC
|
0.005x |
|
SEAZEN GROUP LTD. HD-001
F:6FLA
|
N/A |
|
Lightspeed Commerce Inc
TO:LSPD
|
0.023x |
|
Ningbo Exciton Technology Co Ltd
SHE:300566
|
0.058x |
|
Wacker Neuson SE
F:WAC
|
0.041x |
|
IRSA Inversiones Y Representaciones
NYSE:IRS
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Ascletis Pharma Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Ascletis Pharma Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.93 Billion ≈ $2.26 Billion |
€-416.78 Million ≈ $-487.25 Million |
-0.215x | -24.03% |
| 2024-12-31 | €1.97 Billion ≈ $2.30 Billion |
€-341.58 Million ≈ $-399.34 Million |
-0.174x | -81.81% |
| 2023-12-31 | €2.34 Billion ≈ $2.74 Billion |
€-223.79 Million ≈ $-261.64 Million |
-0.096x | -70.37% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
€-142.45 Million ≈ $-166.54 Million |
-0.056x | -4.17% |
| 2021-12-31 | €2.73 Billion ≈ $3.19 Billion |
€-146.93 Million ≈ $-171.78 Million |
-0.054x | -89.06% |
| 2020-12-31 | €2.98 Billion ≈ $3.49 Billion |
€-84.91 Million ≈ $-99.27 Million |
-0.028x | -27.34% |
| 2019-12-31 | €3.32 Billion ≈ $3.89 Billion |
€-74.34 Million ≈ $-86.91 Million |
-0.022x | +20.65% |
| 2018-12-31 | €3.43 Billion ≈ $4.01 Billion |
€-96.59 Million ≈ $-112.92 Million |
-0.028x | +87.62% |
| 2017-12-31 | €869.83 Million ≈ $1.02 Billion |
€-198.06 Million ≈ $-231.55 Million |
-0.228x | -645.29% |
| 2016-12-31 | €409.08 Million ≈ $478.26 Million |
€-12.50 Million ≈ $-14.61 Million |
-0.031x | -- |
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more